Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$3.18 - $9.74 $44,838 - $137,334
14,100 Added 37.11%
52,100 $185,000
Q2 2024

Aug 14, 2024

BUY
$5.98 - $9.31 $14,950 - $23,275
2,500 Added 7.04%
38,000 $235,000
Q1 2024

May 15, 2024

BUY
$6.7 - $12.0 $92,460 - $165,600
13,800 Added 63.59%
35,500 $335,000
Q4 2023

Feb 14, 2024

BUY
$3.18 - $6.86 $19,398 - $41,846
6,100 Added 39.1%
21,700 $146,000
Q3 2023

Nov 15, 2023

BUY
$3.25 - $6.08 $2,275 - $4,256
700 Added 4.7%
15,600 $69,000
Q2 2023

Aug 23, 2023

SELL
$2.26 - $3.8 $6,101 - $10,260
-2,700 Reduced 15.34%
14,900 $49,000
Q1 2023

May 15, 2023

BUY
$2.83 - $13.99 $49,808 - $246,224
17,600 New
17,600 $50,000
Q2 2022

Aug 15, 2022

BUY
$4.2 - $24.0 $48,720 - $278,400
11,600 New
11,600 $57,000

Others Institutions Holding FULC

About Fulcrum Therapeutics, Inc.


  • Ticker FULC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,038,900
  • Market Cap $237M
  • Description
  • Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystro...
More about FULC
Track This Portfolio

Track Wolverine Trading, LLC Portfolio

Follow Wolverine Trading, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Wolverine Trading, LLC with notifications on news.